Search results
Added:
8 months ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further…
View more
Added:
1 month ago
EHRA 2025 - Positive safety results of the Affera mapping and ablation system for the treatment of ventricular arrhythmias (VA) show a 6% rate of major complication.Dr Frédéric Sacher (IHU Liryc, Bordeaux, FR) joins us on-site at EHRA Congress 2025 to discuss safety results from the European Affera Ventricular Arrhythmia Ablation Registry, investigating VA ablation with the Affera Sphere-9…
View more
Added:
7 months ago
HFSA 24 - We are joined virtually by Dr Sanjiv Shah to discuss the primary results from EMBARK HFpEF (NCT04766892).EMBARK HFpEF is a phase 2a proof-of-concept study assessing the safety, tolerability and preliminary efficacy of mavacamten treatment on myosin biomarkers in patients with heart failure with preserved ejection fractions (HFpEF) and elevated NT-proBNP.Interview Questions:What is the…
View more
Added:
1 year ago
In this insightful interview, investigator, Prof Raj R Makkar(Cedars-Sinai Heart Institute, US) joins us to discuss the outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves.
Prof Makkar and his team used the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry to address a series of questions regarding the safety…
View more
Added:
1 year ago
EuroPCR 24 - In this succinct interview, we are joined by Dr Hans-Josef Feistritzer (University of Leipzig, DE) to discuss the findings of the SOLVE-TAVI Trial.In recent years, trials such as CHOICE, REPRISE III, the SCOPE trial, PORTICO IDE and the SMART trial have privided increasing evidence for direct TACI valve comparisons as device designs improve. TAVI is increasingly performed using local…
View more
Added:
5 months ago
AHA Conference 2024 - Five-Year safety and efficacy follow-up outcomes investigating the non-inferiority of the AMPLATZER Amulet device (Abbott Medical Devices) against the commercially available WATCHMAN (Boston Scientific) device.Dr Dhanunjaya Lakkireddy (Kansas City Heart Rhythm Institute - HCA Midwest, KS, US) joins us onsite at AHA Conference to discuss the findings from Amulet IDE …
View more
Start date:
Nov 27, 2024
Added:
1 hour ago
ESC HF 25 - Outcomes from a study investigating liver stiffness measurement as a non-invasive method to assess central venous pressure showed immediate results at bedside obtained in >4 minutes, with the procedure easily performed by a trained nurse.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses a pilot validation study investigating liver stiffness as a non-invasive…
View more
Added:
1 month ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene…
View more
Added:
11 months ago
Dr Luca Testa (IRCCS Policlinico San Donato, IT) discusses the results of the XLIMIT Trial at the EuroPCR 2024 congress in Paris, France.In this video interview, Dr Testa explains the technology behind the XLIMUS® drug-eluting stent (Cardionovum®) and its benefits. He also reviews the XLIMIT Trial, detailing the study design, selection criteria and clinical outcomes.Specifically, the 6 to 9…
View more
